Загрузка страницы
Все видеоНовые видеоПопулярные видеоКатегории видео

MCRT Baltimore 2018: Immunotherapy for Multiple Myeloma by Ivan Borrello, MD

Dr. Borrello speaks about the integration of immunotherapy treatments into myeloma therapy. Immunotherapies have the potential to use the immune system to prevent disease progression and improve response to treatment with existing drugs. Checkpoint inhibitors, IMiDs, vaccines and CAR-T cells are revolutionizing the field of immunotherapy and present promising opportunities for the future.

Видео MCRT Baltimore 2018: Immunotherapy for Multiple Myeloma by Ivan Borrello, MD канала HealthTree Foundation for Multiple Myeloma
Показать
Комментарии отсутствуют
Введите заголовок:

Введите адрес ссылки:

Введите адрес видео с YouTube:

Зарегистрируйтесь или войдите с
Информация о видео
24 апреля 2018 г. 4:59:37
00:28:35
HealthTree Foundation for Multiple Myeloma
Правообладателям
Жалоба
Комментарии
Другие видео канала
Round Table Audience Q&A Two | RT Irvine, CA Nov 5, 2022Round Table Audience Q&A Two | RT Irvine, CA Nov 5, 2022CELMoDs® Mezigdomide | Paul Richardson, MD | IMS 2022CELMoDs® Mezigdomide | Paul Richardson, MD | IMS 2022The HealthTree Foundation 10 Year AnniversaryThe HealthTree Foundation 10 Year AnniversaryMedicare 101 for Myeloma Patients: What You Need to Know for 2023Medicare 101 for Myeloma Patients: What You Need to Know for 2023Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 | Luciano Costa, MD | EHA 2024Mezigdomide, Tazemetostat, and Dex in RRMM: Results from CA057-003 | Luciano Costa, MD | EHA 2024Exciting Advances in Myeloma Treatment | Timothy Schmidt, MD | ASCO 2023Exciting Advances in Myeloma Treatment | Timothy Schmidt, MD | ASCO 2023ImmunoPET- an Advanced Companion to MRD TestingImmunoPET- an Advanced Companion to MRD TestingHealth Disparities Related to CAR-T Therapy in Myeloma | Samer Al Hadidi, MD | ASH 2021Health Disparities Related to CAR-T Therapy in Myeloma | Samer Al Hadidi, MD | ASH 2021First-line Vs. Second-Line Treatment | Matthew LeBlanc, PhD | IMS 2022First-line Vs. Second-Line Treatment | Matthew LeBlanc, PhD | IMS 2022MASTER Trial Update: MRD based response adaptive therapy | Luciano Costa, MD, PhD | ASH 2021MASTER Trial Update: MRD based response adaptive therapy | Luciano Costa, MD, PhD | ASH 2021Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022Quad Therapies and Side Effects | Nathan Sweeney, PhD | ASH 2022iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021iSTOPMM study and early MGUS and SMM screening | Joshua Richter, MD | ASH 2021MCRT San Diego 2020: Myeloma Expert Panel – Q&A Afternoon SessionMCRT San Diego 2020: Myeloma Expert Panel – Q&A Afternoon SessionBenjamin Derman, MD | MCRT Chicago, Illinois April 30, 2022Benjamin Derman, MD | MCRT Chicago, Illinois April 30, 2022Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022Vaccinations & iStopMM Trial | Natalie Callander, MD | IMS 2022IMS Updates | Saad Usmani, MD, FACP | IMS 2022IMS Updates | Saad Usmani, MD, FACP | IMS 2022Ide-cel Without Front-Line ASCT: KARMMA-2 Cohort 2B | Xavier Leleu, MD, MSc, PhD, EHA 2024Ide-cel Without Front-Line ASCT: KARMMA-2 Cohort 2B | Xavier Leleu, MD, MSc, PhD, EHA 2024Hope for the Future in Black Myeloma- A Black Myeloma Health PanelHope for the Future in Black Myeloma- A Black Myeloma Health PanelBike The Coast Day 6Bike The Coast Day 6Why Stem Cells Matter - William Matsui, MD | RT Austin, TX Mar 25, 2023Why Stem Cells Matter - William Matsui, MD | RT Austin, TX Mar 25, 2023Benefit Study IsaRVd vs IsaRd NDMM TI | Xavier Leleu, MD, MSc, PhD | EHA 2024Benefit Study IsaRVd vs IsaRd NDMM TI | Xavier Leleu, MD, MSc, PhD | EHA 2024
Статистика портала
Яндекс.Метрика
© 2008-2024 «Информационно-развлекательный портал города Верхняя Салда»
| Карта портала | Реклама | Контакты | Сообщить об ошибке | Соглашения
salda.ws salda.ws@mail.ru
Сейчас на сайте: 512 Статистика портала